MedTrace Logo

Effects of Pentazocine Versus Lorazepam on Manic Symptoms

NCT00431184 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-03-06

Study results available
· View outcomes & findings →

Summary

Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study. We will examine whether pentazocine, an agent with kappa-opiate activity, decreases manic symptoms.

Conditions

Interventions

DRUG

Pentazocine

see arms description

DRUG

Lorazepam

see arms description

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Mclean Hospital

    lead OTHER

Principal Investigators

  • Beth L Murphy, MD/PhD · Mclean Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00431184 on ClinicalTrials.gov